McKesson stock gains 2.06 percent as CVS pact extends to 2032
Published on 10/05/2026 at 21:39 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
McKesson stock (ISIN US58155Q1031) was trading at USD 920.87 on the NYSE on October 5, 2026, up USD 18.59 or 2.06 percent from the prior close. The latest company catalyst is a planned extension of McKesson's pharmaceutical distribution relationship with CVS Health through June 2032, according to Business Wire on October 1, 2026.
CVS agreement extends to 2032
The agreement in principle covers mail-order and specialty pharmacies, retail pharmacies and distribution centers. McKesson reaffirmed fiscal 2027 adjusted EPS guidance of USD 44.20-45.00 and a long-term adjusted EPS growth target of 13 percent to 16 percent in the same October 1 release from Business Wire.
The renewal remains an agreement in principle rather than a completed definitive contract. McKesson identified negotiation delays, failure to sign the final agreement and lower-than-expected operational benefits as risks in the release, giving the commercial relationship a clear execution checkpoint.
Quarterly growth meets higher guidance
McKesson's fiscal Q1 2027, covering April through June 2026, produced revenue of USD 105.4 billion, up 7.7 percent year over year, while adjusted EPS increased 20.2 percent to USD 9.93 from USD 8.26, according to Financial Report Insights.
The quarter also exposed an important split in the earnings picture. GAAP diluted EPS fell 17.6 percent to USD 5.15 from USD 6.25, while the company removed non-cash and transaction-related items in its adjusted measure. For investors, the difference means the next report will be judged on both operating growth and the accounting effects linked to the Medical-Surgical separation.
McKesson's fiscal 2027 adjusted EPS guidance of USD 44.20-45.00 is USD 0.40 higher at both ends than the prior USD 43.80-44.60 range, according to Business Wire.
Consensus target remains above price
MarketBeat reports a Moderate Buy consensus based on 14 Buy ratings and four Hold ratings, with an average target of USD 973.44, according to MarketBeat on October 5, 2026. That target is 5.71 percent above the USD 920.87 NYSE price, a gap that leaves the upcoming earnings release as the next measurable test of the valuation.
Business Wire says McKesson will release fiscal Q2 2027 results after the market close on November 4, 2026, followed by a conference call at 4:30 p.m. ET.
McKesson stock trades below its yearly high
At USD 920.87 on October 5, 2026, McKesson stock stood 7.82 percent below its 52-week high of USD 999.00 and 27.25 percent above its 52-week low of USD 723.68. Market capitalization was USD 107.8 billion, with 325,684 shares traded at the recorded time.
McKesson stock facts
- Company: McKesson Corporation
- ISIN: US58155Q1031
- WKN: 893953
- Ticker: MCK
- Trading venue: NYSE
- Price (as of October 5, 2026, 3:38 p.m. ET): USD 920.87
- Market capitalization: USD 107.8 billion (as of October 5, 2026)
- 52-week range: USD 723.68-999.00 (as of October 5, 2026)
- Sector / Industry: Healthcare / Healthcare services and information technology
- Index membership: S&P 500
Upcoming dates for McKesson stock
- November 4, 2026: Fiscal Q2 2027 results after market close and earnings call at 4:30 p.m. ET
